Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ascomycins in dermatology

C Paul1, V C Ho

  • 1Novartis Pharma AG, Basel, Switzerland.

Seminars in Cutaneous Medicine and Surgery
|December 22, 1998
PubMed
Summary
This summary is machine-generated.

Ascomycin derivatives, like SDZ ASM 981, offer a new approach to treating inflammatory skin conditions by blocking cytokine synthesis. This macrolactam shows promise as a safer alternative to corticosteroids for conditions such as atopic dermatitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty in End-Stage Renal Disease Patients under Dialysis and Its Association with Clinical and Biochemical Markers.

The Journal of frailty & aging·2017
Same author

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.

The British journal of dermatology·2017
Same author

Non-surgical treatments for hidradenitis suppurativa: A systematic review.

Annales de chirurgie plastique et esthetique·2017
Same author

Recurrent epistaxis: predicting risk of 30-day readmission, derivation and validation of RHINO-ooze score.

Rhinology·2017
Same author

Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

Authorship selection in industry-sponsored publications of dermatology clinical trials.

The British journal of dermatology·2017
Same journal

Systemic therapy for advanced cutaneous squamous cell carcinoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Atypical Fibroxanthoma.

Seminars in cutaneous medicine and surgery·2019
Same journal

Introduction, High-Risk Skin Cancer.

Seminars in cutaneous medicine and surgery·2019
Same journal

Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care.

Seminars in cutaneous medicine and surgery·2019
Same journal

MoleMapper: an application for crowdsourcing mole images to advance melanoma early-detection research.

Seminars in cutaneous medicine and surgery·2019
Same journal

Digital imaging applications and informatics in dermatology.

Seminars in cutaneous medicine and surgery·2019
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Ascomycin derivatives are novel macrolactams investigated for anti-inflammatory properties.
  • These compounds target the synthesis of Th1 and Th2 cytokines, crucial in inflammatory responses.
  • Current treatments for inflammatory skin diseases, like topical corticosteroids, have drawbacks.

Purpose of the Study:

  • To evaluate the efficacy and safety of ascomycin derivatives, specifically SDZ ASM 981, for treating skin diseases.
  • To explore SDZ ASM 981 as a potential alternative to topical corticosteroids.

Main Methods:

  • Evaluation of SDZ ASM 981's anti-inflammatory activity in animal models of allergic contact dermatitis.
  • Assessment of topical SDZ ASM 981 efficacy in human clinical studies for atopic dermatitis, allergic contact dermatitis, and psoriasis.

Related Experiment Videos

  • Monitoring for adverse effects, including skin atrophy.

    • Main Results:

    • SDZ ASM 981 demonstrated high anti-inflammatory activity in animal models without inducing skin atrophy.
    • Topical application of SDZ ASM 981 proved effective in treating atopic dermatitis and allergic contact dermatitis.
    • Clinical studies indicated effectiveness in psoriasis under semi-occlusive conditions.

    Conclusions:

    • SDZ ASM 981 is a promising ascomycin derivative with significant anti-inflammatory effects for skin diseases.
    • It offers a potential therapeutic option that may overcome limitations associated with topical corticosteroids.
    • Further research is ongoing to fully establish its efficacy and safety profile.